{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:37:29Z","timestamp":1793925449787,"version":"4.8.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41582-024-01034-x","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:01:57Z","timestamp":1730707317000},"page":"695-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":226,"title":["Parkinson disease therapy: current strategies and future research priorities"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5763-0033","authenticated-orcid":false,"given":"Fabrizio","family":"Stocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Bravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2796-5676","authenticated-orcid":false,"given":"Aron","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"1034_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"GBD 2015 Neurological Disorders Collaborator Group.","year":"2017","unstructured":"GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 16, 877\u2013897 (2017).","journal-title":"Lancet Neurol."},{"key":"1034_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey, E. R., Sherer, T., Okun, M. S. & Bloem, B. R. The emerging evidence of the Parkinson pandemic. J. Parkinsons Dis. 8, S3\u2013S8 (2018).","journal-title":"J. Parkinsons Dis."},{"key":"1034_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3233\/JPD-140446","volume":"4","author":"LA Uebelacker","year":"2014","unstructured":"Uebelacker, L. A., Epstein-Lubow, G., Lewis, T., Broughton, M. K. & Friedman, J. H. A survey of Parkinson\u2019s disease patients: most bothersome symptoms and coping preferences. J. Parkinsons Dis. 4, 717\u2013723 (2014).","journal-title":"J. Parkinsons Dis."},{"key":"1034_CR4","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1002\/mdc3.13786","volume":"10","author":"A Antonini","year":"2023","unstructured":"Antonini, A., Emmi, A. & Campagnolo, M. Beyond the dopaminergic system: lessons learned from levodopa resistant symptoms in Parkinson\u2019s disease. Mov. Disord. Clin. Pract. 10, S50\u2013S55 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"1034_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40265-016-0566-3","volume":"76","author":"D Vijayakumar","year":"2016","unstructured":"Vijayakumar, D. & Jankovic, J. Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. Drugs 76, 759\u2013777 (2016).","journal-title":"Drugs"},{"key":"1034_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/mds.26125","volume":"30","author":"CC Aquino","year":"2015","unstructured":"Aquino, C. C. & Fox, S. H. Clinical spectrum of levodopa-induced complications. Mov. Disord. 30, 80\u201389 (2015).","journal-title":"Mov. Disord."},{"key":"1034_CR7","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mds.27340","volume":"33","author":"A Antonini","year":"2018","unstructured":"Antonini, A., Moro, E., Godeiro, C. & Reichmann, H. Medical and surgical management of advanced Parkinson\u2019s disease. Mov. Disord. 33, 900\u2013908 (2018).","journal-title":"Mov. Disord."},{"key":"1034_CR8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2113489119","volume":"119","author":"JI Ayers","year":"2022","unstructured":"Ayers, J. I. et al. Different \u03b1-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy. Proc. Natl Acad. Sci. USA 119, e2113489119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1034_CR9","doi-asserted-by":"publisher","first-page":"168011","DOI":"10.1016\/j.jmb.2023.168011","volume":"435","author":"RWL So","year":"2023","unstructured":"So, R. W. L. & Watts, J. C. \u03b1-Synuclein conformational strains as drivers of phenotypic heterogeneity in neurodegenerative diseases. J. Mol. Biol. 435, 168011 (2023).","journal-title":"J. Mol. Biol."},{"key":"1034_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi, P. et al. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 14, 176 (2023).","journal-title":"Cell Death Dis."},{"key":"1034_CR11","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","volume":"97","author":"T Pringsheim","year":"2021","unstructured":"Pringsheim, T. et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary. Neurology 97, 942\u2013957 (2021).","journal-title":"Neurology"},{"key":"1034_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1586\/14737175.2015.1001747","volume":"15","author":"P Stathis","year":"2015","unstructured":"Stathis, P., Konitsiotis, S. & Antonini, A. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. Expert Rev. Neurother. 15, 207\u2013213 (2015).","journal-title":"Expert Rev. Neurother."},{"issue":"Suppl. 1","key":"1034_CR13","first-page":"Abstract 41","volume":"38","author":"C Clarke","year":"2023","unstructured":"Clarke, C. et al. 15-Year effects of initiating treatment for Parkinson\u2019s disease with dopamine agonists or monoamine oxidase B inhibitors compared with levodopa: final results of PD MED early disease randomisation [abstract]. Mov. Disord. 38 (Suppl. 1), Abstract 41 (2023).","journal-title":"Mov. Disord."},{"key":"1034_CR14","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1002\/mds.28726","volume":"36","author":"CW Olanow","year":"2021","unstructured":"Olanow, C. W., Poewe, W., Rascol, O. & Stocchi, F. On-demand therapy for OFF episodes in Parkinson\u2019s disease. Mov. Disord. 36, 2244\u20132253 (2021).","journal-title":"Mov. Disord."},{"key":"1034_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow, C. W., Obeso, J. A. & Stocchi, F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol. 5, 677\u2013687 (2006).","journal-title":"Lancet Neurol."},{"key":"1034_CR16","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s40263-022-00963-9","volume":"36","author":"A Antonini","year":"2022","unstructured":"Antonini, A. et al. Comparative effectiveness of device-aided therapies on quality of life and off-time in advanced Parkinson\u2019s disease: a systematic review and Bayesian network meta-analysis. CNS Drugs 36, 1269\u20131283 (2022).","journal-title":"CNS Drugs"},{"key":"1034_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3233\/JPD-230372","volume":"14","author":"A Demailly","year":"2024","unstructured":"Demailly, A., Moreau, C. & Devos, D. Effectiveness of continuous dopaminergic therapies in Parkinson\u2019s disease: a review of L-DOPA pharmacokinetics\/pharmacodynamics. J. Parkinsons Dis. 14, 925\u2013939 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"1034_CR18","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/ene.15734","volume":"30","author":"V Leta","year":"2023","unstructured":"Leta, V. et al. Gastrointestinal barriers to levodopa transport and absorption in Parkinson\u2019s disease. Eur. J. Neurol. 30, 1465\u20131480 (2023).","journal-title":"Eur. J. Neurol."},{"key":"1034_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000300647","volume":"63","author":"F Stocchi","year":"2010","unstructured":"Stocchi, F., Jenner, P. & Obeso, J. A. When do levodopa motor fluctuations first appear in Parkinson\u2019s disease? Eur. Neurol. 63, 257\u2013266 (2010).","journal-title":"Eur. Neurol."},{"key":"1034_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fneur.2014.00242","volume":"5","author":"MA Cenci","year":"2014","unstructured":"Cenci, M. A. Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front. Neurol. 5, 242 (2014).","journal-title":"Front. Neurol."},{"key":"1034_CR21","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","volume":"9","author":"P Calabresi","year":"2010","unstructured":"Calabresi, P., Filippo, M. D., Ghiglieri, V., Tambasco, N. & Picconi, B. Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: filling the bench-to-bedside gap. Lancet Neurol. 9, 1106\u20131117 (2010).","journal-title":"Lancet Neurol."},{"key":"1034_CR22","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.2147\/DDDT.S302673","volume":"15","author":"G Abbruzzese","year":"2021","unstructured":"Abbruzzese, G., Barone, P., Lopiano, L. & Stocchi, F. The current evidence for the use of safinamide for the treatment of Parkinson\u2019s disease. Drug Des. Devel. Ther. 15, 2507\u20132517 (2021).","journal-title":"Drug Des. Devel. Ther."},{"key":"1034_CR23","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/mds.29193","volume":"37","author":"JJ Ferreira","year":"2022","unstructured":"Ferreira, J. J. et al. Effect of opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson\u2019s disease. Mov. Disord. 37, 2272\u20132283 (2022).","journal-title":"Mov. Disord."},{"key":"1034_CR24","doi-asserted-by":"publisher","first-page":"994114","DOI":"10.3389\/fneur.2022.994114","volume":"13","author":"JF Rocha","year":"2022","unstructured":"Rocha, J. F. et al. The safety\/tolerability of opicapone when used early in Parkinson\u2019s disease patients with levodopa-induced motor fluctuations: a post-hoc analysis of BIPARK-I and II. Front. Neurol. 13, 994114 (2022).","journal-title":"Front. Neurol."},{"key":"1034_CR25","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","volume":"368","author":"WMM Schuepbach","year":"2013","unstructured":"Schuepbach, W. M. M. et al. Neurostimulation for Parkinson\u2019s disease with early motor complications. N. Engl. J. Med. 368, 610\u2013622 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1034_CR26","doi-asserted-by":"publisher","first-page":"105431","DOI":"10.1016\/j.parkreldis.2023.105431","volume":"111","author":"TH Ko","year":"2023","unstructured":"Ko, T. H. et al. Magnetic resonance-guided focused ultrasound surgery for Parkinson\u2019s disease: a mini-review and comparison between deep brain stimulation. Parkinsonism Relat. Disord. 111, 105431 (2023).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1034_CR27","doi-asserted-by":"crossref","unstructured":"Coelho, M. & Ferreira, J. In: Movement Disorders Curricula (eds Falup-Pecurariu, C., Ferreira, J., Martinez-Martin, P. & Chaudhuri, K. R.) 129\u2013137 (Springer, 2017).","DOI":"10.1007\/978-3-7091-1628-9_13"},{"key":"1034_CR28","doi-asserted-by":"publisher","first-page":"760518","DOI":"10.3389\/fneur.2021.760518","volume":"12","author":"M Garon","year":"2022","unstructured":"Garon, M. et al. Quantification of brain \u03b2-amyloid load in Parkinson\u2019s disease with mild cognitive impairment: a PET\/MRI study. Front. Neurol. 12, 760518 (2022).","journal-title":"Front. Neurol."},{"key":"1034_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3233\/JPD-239901","volume":"13","author":"K McFarthing","year":"2023","unstructured":"McFarthing, K. et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2023 update. J. Parkinsons Dis. 13, 427\u2013439 (2023).","journal-title":"J. Parkinsons Dis."},{"key":"1034_CR30","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2023.2679","volume":"80","author":"RA Hauser","year":"2023","unstructured":"Hauser, R. A. et al. IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in Parkinson disease: the RISE-PD randomized clinical trial. JAMA Neurol. 80, 1062\u20131069 (2023).","journal-title":"JAMA Neurol."},{"key":"1034_CR31","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau, M. J. et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 21, 1099\u20131109 (2022).","journal-title":"Lancet Neurol."},{"key":"1034_CR32","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1474-4422(24)00052-8","volume":"23","author":"AJ Espay","year":"2024","unstructured":"Espay, A. J. et al. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson\u2019s disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol. 23, 465\u2013476 (2024).","journal-title":"Lancet Neurol."},{"key":"1034_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/mds.27610","volume":"34","author":"CW Olanow","year":"2019","unstructured":"Olanow, C. W. et al. Continuous versus intermittent oral administration of levodopa in Parkinson\u2019s disease patients with motor fluctuations: a pharmacokinetics, safety, and efficacy study. Mov. Disord. 34, 425\u2013429 (2019).","journal-title":"Mov. Disord."},{"key":"1034_CR34","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/mds.29824","volume":"39","author":"CW Olanow","year":"2024","unstructured":"Olanow, C. W. et al. Continuous levodopa delivery with an intraoral micropump system: an open-label pharmacokinetics and clinical study. Mov. Disord. 39, 945\u2013954 (2024).","journal-title":"Mov. Disord."},{"key":"1034_CR35","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/mds.28027","volume":"35","author":"CW Olanow","year":"2020","unstructured":"Olanow, C. W., Standaert, D. G., Kieburtz, K., Viegas, T. X. & Moreadith, R. Once\u2010weekly subcutaneous delivery of polymer\u2010linked rotigotine (SER\u2010214) provides continuous plasma levels in Parkinson\u2019s disease patients. Mov. Disord. 35, 1055\u20131061 (2020).","journal-title":"Mov. Disord."},{"key":"1034_CR36","doi-asserted-by":"publisher","first-page":"175628642091129","DOI":"10.1177\/1756286420911296","volume":"13","author":"R Riesenberg","year":"2020","unstructured":"Riesenberg, R., Werth, J., Zhang, Y., Duvvuri, S. & Gray, D. PF-06649751 efficacy and safety in early Parkinson\u2019s disease: a randomized, placebo-controlled trial. Ther. Adv. Neurol. Disord. 13, 175628642091129 (2020).","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"Suppl. 1","key":"1034_CR37","first-page":"Abstract 22","volume":"38","author":"A Antonini","year":"2023","unstructured":"Antonini, A. et al. Results from IRL790C005 \u2014 a randomized, double-blind, placebo-controlled phase IIb study evaluating the efficacy of mesdopetam on daily on-time without troublesome dyskinesia in patients with Parkinson\u2019s disease [abstract]. Mov. Disord. 38 (Suppl. 1), Abstract 22 (2023).","journal-title":"Mov. Disord."},{"key":"1034_CR38","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/mds.27724","volume":"34","author":"JD Heiss","year":"2019","unstructured":"Heiss, J. D. et al. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson\u2019s disease. Mov. Disord. 34, 1073\u20131078 (2019).","journal-title":"Mov. Disord."},{"key":"1034_CR39","unstructured":"Bayer Global. AskBio phase Ib trial of AB-1005 gene therapy in patients with Parkinson\u2019s disease meets primary endpoint. https:\/\/www.bayer.com\/en\/ca\/askbio-phase-ib-trial-of-ab-1005-gene-therapy-in-patients-with-parkinsons-disease-meets-primary (2024)."},{"issue":"Suppl. 1","key":"1034_CR40","first-page":"Abstract 960","volume":"39","author":"C Henchcliffe","year":"2024","unstructured":"Henchcliffe, C. et al. Motor and non-motor outcomes of bemdaneprocel in people with Parkinson\u2019s disease: results up to 24 months from a phase 1 study [abstract]. Mov. Disord. 39 (Suppl. 1), Abstract 960 (2024).","journal-title":"Mov. Disord."},{"key":"1034_CR41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10286-021-00827-0","volume":"31","author":"H Kaufmann","year":"2021","unstructured":"Kaufmann, H. et al. Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial. Clin. Auton. Res. 31, 699\u2013711 (2021).","journal-title":"Clin. Auton. Res."},{"key":"1034_CR42","volume":"15","author":"P Hoxhaj","year":"2023","unstructured":"Hoxhaj, P. et al. Ampreloxetine versus droxidopa in neurogenic orthostatic hypotension: a comparative review. Cureus 15, e38907 (2023).","journal-title":"Cureus"},{"key":"1034_CR43","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.parkreldis.2013.10.027","volume":"20","author":"F Stocchi","year":"2014","unstructured":"Stocchi, F. et al. Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat. Disord. 20, 204\u2013211 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1034_CR44","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.3390\/brainsci12111466","volume":"12","author":"D Santos Garc\u00eda","year":"2022","unstructured":"Santos Garc\u00eda, D. et al. Vortioxetine improves depressive symptoms and cognition in Parkinson\u2019s disease patients with major depression: an open-label prospective study. Brain Sci. 12, 1466 (2022).","journal-title":"Brain Sci."},{"key":"1034_CR45","unstructured":"BioSpace. CuraSen Therapeutics to present phase 2 data showing rapid-onset cognition and mood benefit with CST-103\/CST-107 (clenbuterol\/nadolol) in Parkinson\u2019s Disease at the Alzheimer\u2019s Disease and Parkinson\u2019s Disease (AD\/PD\u201923) Conference. https:\/\/www.biospace.com\/article\/releases\/curasen-therapeutics-to-present-phase-2-data-showing-rapid-onset-cognition-and-mood-benefit-with-cst-103-cst-107-clenbuterol-nadolol-in-parkinson-s-disease-at-the-alzheimer-s-disease-and-parkinson-s-disease-ad-pd-23-conference\/ (2023)."},{"key":"1034_CR46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin, S. et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations. JAMA Neurol. 77, 427\u2013434 (2020).","journal-title":"JAMA Neurol."},{"key":"1034_CR47","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1021\/acsmedchemlett.9b00216","volume":"10","author":"AF Abdel-Magid","year":"2019","unstructured":"Abdel-Magid, A. F. LRRK2 kinase inhibitors as possible therapy for Parkinson\u2019s disease and other neurodegenerative disorders. ACS Med. Chem. Lett. 10, 846\u2013847 (2019).","journal-title":"ACS Med. Chem. Lett."},{"key":"1034_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nan.12298","volume":"42","author":"K Del Tredici","year":"2016","unstructured":"Del Tredici, K. & Braak, H. Review: sporadic Parkinson\u2019s disease: development and distribution of \u03b1-synuclein pathology. Neuropathol. Appl. Neurobiol. 42, 33\u201350 (2016).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"1034_CR49","doi-asserted-by":"publisher","first-page":"17797","DOI":"10.1073\/pnas.1113260108","volume":"108","author":"W Wang","year":"2011","unstructured":"Wang, W. et al. A soluble \u03b1-synuclein construct forms a dynamic tetramer. Proc. Natl Acad. Sci. USA 108, 17797\u201317802 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1034_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T Bartels","year":"2011","unstructured":"Bartels, T., Choi, J. G. & Selkoe, D. J. \u03b1-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107\u2013110 (2011).","journal-title":"Nature"},{"key":"1034_CR51","doi-asserted-by":"publisher","first-page":"7929","DOI":"10.1074\/jbc.C113.538249","volume":"289","author":"N Gould","year":"2014","unstructured":"Gould, N. et al. Evidence of native \u03b1-synuclein conformers in the human Brain. J. Biol. Chem. 289, 7929\u20137934 (2014).","journal-title":"J. Biol. Chem."},{"key":"1034_CR52","doi-asserted-by":"publisher","first-page":"105432","DOI":"10.1016\/j.parkreldis.2023.105432","volume":"111","author":"AJ Espay","year":"2023","unstructured":"Espay, A. J. & McFarthing, K. Alpha-synuclein and the Parkinson\u2019s disease drug pipeline. Parkinsonism Relat. Disord. 111, 105432 (2023).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1034_CR53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/mds.26481","volume":"31","author":"AL Bergstr\u00f6m","year":"2016","unstructured":"Bergstr\u00f6m, A. L., Kallunki, P. & Fog, K. Development of passive immunotherapies for synucleinopathies. Mov. Disord. 31, 203\u2013213 (2016).","journal-title":"Mov. Disord."},{"key":"1034_CR54","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano, G. et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N. Engl. J. Med. 387, 421\u2013432 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1034_CR55","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang, A. E. et al. Trial of cinpanemab in early Parkinson\u2019s disease. N. Engl. J. Med. 387, 408\u2013420 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1034_CR56","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano, G. et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat. Med. 30, 1096\u20131103 (2024).","journal-title":"Nat. Med."},{"key":"1034_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34490-9","volume":"8","author":"DL Price","year":"2018","unstructured":"Price, D. L. et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease. Sci. Rep. 8, 16165 (2018).","journal-title":"Sci. Rep."},{"key":"1034_CR58","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/brain\/aww238","volume":"139","author":"W Wrasidlo","year":"2016","unstructured":"Wrasidlo, W. et al. A de novo compound targeting \u03b1-synuclein improves deficits in models of Parkinson\u2019s disease. Brain 139, 3217\u20133236 (2016).","journal-title":"Brain"},{"key":"1034_CR59","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/mds.29170","volume":"37","author":"JW Smit","year":"2022","unstructured":"Smit, J. W. et al. Phase 1\/1b studies of UCB0599, an oral inhibitor of \u03b1\u2010synuclein misfolding, including a randomized study in Parkinson\u2019s disease. Mov. Disord. 37, 2045\u20132056 (2022).","journal-title":"Mov. Disord."},{"key":"1034_CR60","first-page":"25","volume":"10","author":"C Fang","year":"2023","unstructured":"Fang, C. et al. Buntanetap, a novel translational inhibitor of multiple neurotoxic proteins, proves to be safe and promising in both Alzheimer\u2019s and Parkinson\u2019s patients. J. Prev. Alzheimers Dis. 10, 25\u201333 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1034_CR61","doi-asserted-by":"publisher","first-page":"105281","DOI":"10.1016\/j.parkreldis.2023.105281","volume":"108","author":"RR Walsh","year":"2023","unstructured":"Walsh, R. R. et al. Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 108, 105281 (2023).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1034_CR62","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00401-016-1648-8","volume":"133","author":"N Dzamko","year":"2017","unstructured":"Dzamko, N. et al. Toll-like receptor 2 is increased in neurons in Parkinson\u2019s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol. 133, 303\u2013319 (2017).","journal-title":"Acta Neuropathol."},{"key":"1034_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02720-1","volume":"20","author":"Y Cheng","year":"2023","unstructured":"Cheng, Y. et al. \u03b1-Synuclein induces prodromal symptoms of Parkinson\u2019s disease via activating TLR2\/MyD88\/NF-\u03baB pathway in Schwann cells of vagus nerve in a rat model. J. Neuroinflammation 20, 36 (2023).","journal-title":"J. Neuroinflammation"},{"key":"1034_CR64","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/clpt.2013.150","volume":"94","author":"M Reilly","year":"2013","unstructured":"Reilly, M. et al. Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody. Clin. Pharmacol. Ther. 94, 593\u2013600 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1034_CR65","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner, J. et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol. 125, 795\u2013813 (2013).","journal-title":"Acta Neuropathol."},{"key":"1034_CR66","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1021\/acschemneuro.7b00325","volume":"8","author":"D Matthes","year":"2017","unstructured":"Matthes, D., Gapsys, V., Griesinger, C. & de Groot, B. L. Resolving the atomistic modes of anle138b inhibitory action on peptide oligomer formation. ACS Chem. Neurosci. 8, 2791\u20132808 (2017).","journal-title":"ACS Chem. Neurosci."},{"key":"1034_CR67","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.3233\/JPD-223338","volume":"12","author":"S Jewell","year":"2022","unstructured":"Jewell, S., Herath, A. M. & Gordon, R. Inflammasome activation in Parkinson\u2019s disease. J. Parkinsons Dis. 12, S113\u2013S128 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"1034_CR68","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2217\/nmt-2023-0025","volume":"13","author":"H El Otmani","year":"2023","unstructured":"El Otmani, H., Daghi, M., Tahiri Jouti, N. & Lesage, S. An overview of the worldwide distribution of LRRK2 mutations in Parkinson\u2019s disease. Neurodegener. Dis. Manag. 13, 335\u2013350 (2023).","journal-title":"Neurodegener. Dis. Manag."},{"key":"1034_CR69","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/nn1776","volume":"9","author":"WW Smith","year":"2006","unstructured":"Smith, W. W. et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9, 1231\u20131233 (2006).","journal-title":"Nat. Neurosci."},{"key":"1034_CR70","doi-asserted-by":"publisher","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings, D. et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci. Transl. Med. 14, eabj2658 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1034_CR71","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00401-024-02699-w","volume":"147","author":"RL Walton","year":"2024","unstructured":"Walton, R. L. et al. Role of GBA variants in Lewy body disease neuropathology. Acta Neuropathol. 147, 54 (2024).","journal-title":"Acta Neuropathol."},{"key":"1034_CR72","doi-asserted-by":"publisher","first-page":"175439","DOI":"10.1016\/j.ejphar.2022.175439","volume":"938","author":"SD Chen","year":"2023","unstructured":"Chen, S. D., Chuang, Y. C., Lin, T. K. & Yang, J. L. Alternative role of glucagon-like peptide-1 receptor agonists in neurodegenerative diseases. Eur. J. Pharmacol. 938, 175439 (2023).","journal-title":"Eur. J. Pharmacol."},{"key":"1034_CR73","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","volume":"28","author":"CW Olanow","year":"2013","unstructured":"Olanow, C. W. et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease. Mov. Disord. 28, 1064\u20131071 (2013).","journal-title":"Mov. Disord."},{"key":"1034_CR74","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/mds.21743","volume":"22","author":"RA Hauser","year":"2007","unstructured":"Hauser, R. A. et al. Ten-year follow-up of Parkinson\u2019s disease patients randomized to initial therapy with ropinirole or levodopa. Mov. Disord. 22, 2409\u20132417 (2007).","journal-title":"Mov. Disord."},{"key":"1034_CR75","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1212\/WNL.58.suppl_1.S33","volume":"58","author":"CW Olanow","year":"2002","unstructured":"Olanow, C. W. The role of dopamine agonists in the treatment of early Parkinson\u2019s disease. Neurology 58, S33\u2013S41 (2002).","journal-title":"Neurology"},{"key":"1034_CR76","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/14740338.2020.1804550","volume":"19","author":"F Stocchi","year":"2020","unstructured":"Stocchi, F., Fossati, B. & Torti, M. Safety considerations when using non-ergot dopamine agonists to treat Parkinson\u2019s disease. Expert Opin. Drug Saf. 19, 1155\u20131172 (2020).","journal-title":"Expert Opin. Drug Saf."},{"key":"1034_CR77","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2174\/1871527322666230331121028","volume":"23","author":"E Bezard","year":"2024","unstructured":"Bezard, E. et al. Rationale and development of tavapadon, a D1\/D5-selective partial dopamine agonist for the treatment of Parkinson\u2019s disease. CNS Neurol. Disord. Drug Targets 23, 476\u2013487 (2024).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"1034_CR78","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi, F. et al. Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann. Neurol. 68, 18\u201327 (2010).","journal-title":"Ann. Neurol."},{"key":"1034_CR79","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","volume":"20","author":"O Rascol","year":"2021","unstructured":"Rascol, O., Fabbri, M. & Poewe, W. Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders. Lancet Neurol. 20, 1048\u20131056 (2021).","journal-title":"Lancet Neurol."},{"key":"1034_CR80","doi-asserted-by":"publisher","first-page":"108189","DOI":"10.1016\/j.clineuro.2024.108189","volume":"239","author":"W Wu","year":"2024","unstructured":"Wu, W., Lu, X., Zhang, L. & Hong, D. Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with Parkinson\u2019s disease: systematic review and network meta-analysis. Clin. Neurol. Neurosurg. 239, 108189 (2024).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"1034_CR81","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3233\/JPD-212672","volume":"11","author":"RA Hauser","year":"2021","unstructured":"Hauser, R. A. et al. Efficacy of istradefylline, an adenosine A2A receptor antagonist, as adjunctive therapy to levodopa in Parkinson\u2019s disease: a pooled analysis of 8 phase 2b\/3 trials. J. Parkinsons Dis. 11, 1663\u20131675 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"1034_CR82","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14737175.2023.2176220","volume":"23","author":"A Lees","year":"2023","unstructured":"Lees, A. et al. Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Rev. Neurother. 23, 15\u201324 (2023).","journal-title":"Expert Rev. Neurother."},{"key":"1034_CR83","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s40263-020-00754-0","volume":"34","author":"P Gonzalez-Latapi","year":"2020","unstructured":"Gonzalez-Latapi, P., Bhowmick, S. S., Saranza, G. & Fox, S. H. Non-dopaminergic treatments for motor control in Parkinson\u2019s disease: an update. CNS Drugs 34, 1025\u20131044 (2020).","journal-title":"CNS Drugs"},{"key":"1034_CR84","doi-asserted-by":"publisher","first-page":"061001","DOI":"10.1088\/1741-2552\/ac3267","volume":"18","author":"S Marceglia","year":"2021","unstructured":"Marceglia, S. et al. Deep brain stimulation: is it time to change gears by closing the loop? J. Neural Eng. 18, 061001 (2021).","journal-title":"J. Neural Eng."},{"key":"1034_CR85","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/ner.13407","volume":"25","author":"A Schnitzler","year":"2022","unstructured":"Schnitzler, A. et al. Directional deep brain stimulation for Parkinson\u2019s disease: results of an international crossover study with randomized, double-blind primary endpoint. Neuromodulation 25, 817\u2013828 (2022).","journal-title":"Neuromodulation"},{"key":"1034_CR86","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/mds.29415","volume":"38","author":"W Neumann","year":"2023","unstructured":"Neumann, W., Gilron, R., Little, S. & Tinkhauser, G. Adaptive deep brain stimulation: from experimental evidence toward practical implementation. Mov. Disord. 38, 937\u2013948 (2023).","journal-title":"Mov. Disord."},{"key":"1034_CR87","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1016\/j.clinph.2016.09.004","volume":"127","author":"NG Pozzi","year":"2016","unstructured":"Pozzi, N. G. et al. Distinctive neuronal firing patterns in subterritories of the subthalamic nucleus. Clin. Neurophysiol. 127, 3387\u20133393 (2016).","journal-title":"Clin. Neurophysiol."},{"key":"1034_CR88","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s42466-020-00086-w","volume":"2","author":"C Daniels","year":"2020","unstructured":"Daniels, C. et al. Combined subthalamic and nucleus basalis of Meynert deep brain stimulation for Parkinson\u2019s disease with dementia (DEMPARK-DBS): protocol of a randomized, sham-controlled trial. Neurol. Res. Pract. 2, 41 (2020).","journal-title":"Neurol. Res. Pract."},{"key":"1034_CR89","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41531-021-00185-8","volume":"7","author":"D Bega","year":"2021","unstructured":"Bega, D. et al. Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis. NPJ Parkinsons Dis. 7, 43 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"1034_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243612","volume":"15","author":"M Torti","year":"2020","unstructured":"Torti, M. et al. Effect of family history, occupation and diet on the risk of Parkinson disease: a case-control study. PLoS One 15, e0243612 (2020).","journal-title":"PLoS One"},{"key":"1034_CR91","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2024.0792","volume":"331","author":"CH Gibbons","year":"2024","unstructured":"Gibbons, C. H. et al. Skin biopsy detection of phosphorylated \u03b1-synuclein in patients with synucleinopathies. JAMA 331, 1298 (2024).","journal-title":"JAMA"},{"key":"1034_CR92","doi-asserted-by":"publisher","first-page":"e1944","DOI":"10.1212\/WNL.0000000000207147","volume":"100","author":"A Iranzo","year":"2023","unstructured":"Iranzo, A. et al. Misfolded \u03b1-synuclein assessment in skin and CSF by RT-QuIC in isolated REM sleep behavior disorder. Neurology 100, e1944\u2013e1954 (2023).","journal-title":"Neurology"},{"key":"1034_CR93","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"1034_CR94","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/mds.27110","volume":"32","author":"P Eusebi","year":"2017","unstructured":"Eusebi, P. et al. Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov. Disord. 32, 1389\u20131400 (2017).","journal-title":"Mov. Disord."},{"key":"1034_CR95","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12264-019-00433-1","volume":"36","author":"T Li","year":"2020","unstructured":"Li, T. & Le, W. Biomarkers for Parkinson\u2019s disease: how good are they? Neurosci. Bull. 36, 183\u2013194 (2020).","journal-title":"Neurosci. Bull."},{"key":"1034_CR96","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/mds.28611","volume":"36","author":"NK Majbour","year":"2021","unstructured":"Majbour, N. K. et al. Cerebrospinal \u03b1-synuclein oligomers reflect disease motor severity in DeNoPa longitudinal cohort. Mov. Disord. 36, 2048\u20132056 (2021).","journal-title":"Mov. Disord."},{"key":"1034_CR97","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","volume":"11","author":"NK Majbour","year":"2016","unstructured":"Majbour, N. K. et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson\u2019s disease. Mol. Neurodegener. 11, 7 (2016).","journal-title":"Mol. Neurodegener."},{"key":"1034_CR98","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/mds.26754","volume":"31","author":"NK Majbour","year":"2016","unstructured":"Majbour, N. K. et al. Longitudinal changes in CSF alpha-synuclein species reflect Parkinson\u2019s disease progression. Mov. Disord. 31, 1535\u20131542 (2016).","journal-title":"Mov. Disord."},{"key":"1034_CR99","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi, A. et al. Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies. Nat. Med. 29, 1448\u20131455 (2023).","journal-title":"Nat. Med."},{"key":"1034_CR100","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/brain\/awac115","volume":"145","author":"A Kluge","year":"2022","unstructured":"Kluge, A. et al. Detection of neuron-derived pathological \u03b1-synuclein in blood. Brain 145, 3058\u20133071 (2022).","journal-title":"Brain"},{"key":"1034_CR101","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/mds.29766","volume":"39","author":"A Kluge","year":"2024","unstructured":"Kluge, A. et al. Detecting misfolded \u03b1\u2010synuclein in blood years before the diagnosis of Parkinson\u2019s disease. Mov. Disord. 39, 1289\u20131299 (2024).","journal-title":"Mov. Disord."},{"key":"1034_CR102","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1093\/brain\/awac253","volume":"145","author":"V Chelban","year":"2022","unstructured":"Chelban, V. et al. Neurofilament light levels predict clinical progression and death in multiple system atrophy. Brain 145, 4398\u20134408 (2022).","journal-title":"Brain"},{"key":"1034_CR103","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/mds.28472","volume":"36","author":"S Lerche","year":"2021","unstructured":"Lerche, S. et al. The mutation matters: CSF profiles of GCase, sphingolipids, \u03b1\u2010synuclein in PD GBA. Mov. Disord. 36, 1216\u20131228 (2021).","journal-title":"Mov. Disord."},{"key":"1034_CR104","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuroscience.2019.05.015","volume":"413","author":"X Si","year":"2019","unstructured":"Si, X. et al. Central nervous system-derived exosomal alpha-synuclein in serum may be a biomarker in Parkinson\u2019s disease. Neuroscience 413, 308\u2013316 (2019).","journal-title":"Neuroscience"},{"key":"1034_CR105","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbi.2008.07.003","volume":"23","author":"M Reale","year":"2009","unstructured":"Reale, M. et al. Peripheral cytokines profile in Parkinson\u2019s disease. Brain Behav. Immun. 23, 55\u201363 (2009).","journal-title":"Brain Behav. Immun."},{"key":"1034_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0935-1","volume":"14","author":"LN Eidson","year":"2017","unstructured":"Eidson, L. N. et al. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson\u2019s disease. J. Neuroinflammation 14, 164 (2017).","journal-title":"J. Neuroinflammation"},{"key":"1034_CR107","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fncel.2014.00156","volume":"8","author":"A Vallelunga","year":"2014","unstructured":"Vallelunga, A. et al. Identification of circulating microRNAs for the differential diagnosis of Parkinson\u2019s disease and multiple system atrophy. Front. Cell. Neurosci. 8, 156 (2014).","journal-title":"Front. Cell. Neurosci."},{"key":"1034_CR108","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.parkreldis.2019.04.010","volume":"64","author":"KS Patil","year":"2019","unstructured":"Patil, K. S. et al. Combinatory microRNA serum signatures as classifiers of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 64, 202\u2013210 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1034_CR109","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa, E., Garrido, A., Scholz, S. W. & Poewe, W. Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol. 20, 385\u2013397 (2021).","journal-title":"Lancet Neurol."},{"key":"1034_CR110","doi-asserted-by":"publisher","first-page":"e1267","DOI":"10.1212\/WNL.0000000000010404","volume":"95","author":"LM Chahine","year":"2020","unstructured":"Chahine, L. M. et al. In vivo distribution of \u03b1-synuclein in multiple tissues and biofluids in Parkinson disease. Neurology 95, e1267\u2013e1284 (2020).","journal-title":"Neurology"},{"key":"1034_CR111","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1021\/acschemneuro.8b00383","volume":"10","author":"LY Ma","year":"2019","unstructured":"Ma, L. Y. et al. Alpha-synuclein in peripheral tissues in Parkinson\u2019s disease. ACS Chem. Neurosci. 10, 812\u2013823 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"1034_CR112","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi, M. et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 140, 49\u201362 (2020).","journal-title":"Acta Neuropathol."},{"key":"1034_CR113","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1212\/WNL.0000000000000316","volume":"82","author":"V Donadio","year":"2014","unstructured":"Donadio, V. et al. Skin nerve \u03b1-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology 82, 1362\u20131369 (2014).","journal-title":"Neurology"},{"key":"1034_CR114","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1212\/01.wnl.0000264429.59379.d9","volume":"68","author":"A Minguez-Castellanos","year":"2007","unstructured":"Minguez-Castellanos, A. et al. Do \u03b1-synuclein aggregates in autonomic plexuses predate Lewy body disorders? a cohort study. Neurology 68, 2012\u20132018 (2007).","journal-title":"Neurology"},{"key":"1034_CR115","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mds.29358","volume":"38","author":"A Emmi","year":"2023","unstructured":"Emmi, A. et al. Duodenal alpha\u2010synuclein pathology and enteric gliosis in advanced Parkinson\u2019s disease. Mov. Disord. 38, 885\u2013894 (2023).","journal-title":"Mov. Disord."},{"key":"1034_CR116","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/mds.27380","volume":"33","author":"M Skorvanek","year":"2018","unstructured":"Skorvanek, M. et al. \u03b1-Synuclein antibody 5G4 identifies manifest and prodromal Parkinson\u2019s disease in colonic mucosa. Mov. Disord. 33, 1366\u20131368 (2018).","journal-title":"Mov. Disord."},{"key":"1034_CR117","first-page":"4687530","volume":"2020","author":"G Beck","year":"2020","unstructured":"Beck, G. et al. Detection of phosphorylated alpha-synuclein in the muscularis propria of the gastrointestinal tract is a sensitive predictor for Parkinson\u2019s disease. Parkinsons Dis. 2020, 4687530 (2020).","journal-title":"Parkinsons Dis."},{"key":"1034_CR118","doi-asserted-by":"publisher","first-page":"8666","DOI":"10.3390\/ijms21228666","volume":"21","author":"D Fricova","year":"2020","unstructured":"Fricova, D., Harsanyiova, J. & Kralova Trancikova, A. Alpha-synuclein in the gastrointestinal tract as a potential biomarker for early detection of Parkinson\u2019s disease. Int. J. Mol. Sci. 21, 8666 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1034_CR119","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.parkreldis.2020.08.020","volume":"80","author":"BN Harapan","year":"2020","unstructured":"Harapan, B. N. et al. No enhanced (p-) \u03b1-synuclein deposition in gastrointestinal tissue of Parkinson\u2019s disease patients. Parkinsonism Relat. Disord. 80, 82\u201388 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1034_CR120","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.24648","volume":"79","author":"MG Stokholm","year":"2016","unstructured":"Stokholm, M. G., Danielsen, E. H., Hamilton-Dutoit, S. J. & Borghammer, P. Pathological \u03b1-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol. 79, 940\u2013949 (2016).","journal-title":"Ann. Neurol."},{"key":"1034_CR121","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3233\/JPD-202481","volume":"11","author":"P Borghammer","year":"2021","unstructured":"Borghammer, P. The \u03b1-synuclein origin and connectome model (SOC model) of Parkinson\u2019s disease: explaining motor asymmetry, non-motor phenotypes, and cognitive decline. J. Parkinsons Dis. 11, 455\u2013474 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"1034_CR122","first-page":"433","volume":"5","author":"FM Lu","year":"2015","unstructured":"Lu, F. M. & Yuan, Z. PET\/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. Quant. Imaging Med. Surg. 5, 433\u2013447 (2015).","journal-title":"Quant. Imaging Med. Surg."},{"key":"1034_CR123","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/mds.27183","volume":"33","author":"W Li","year":"2018","unstructured":"Li, W. et al. 11C\u2010PE2I and 18F\u2010dopa PET for assessing progression rate in Parkinson\u2019s: a longitudinal study. Mov. Disord. 33, 117\u2013127 (2018).","journal-title":"Mov. Disord."},{"key":"1034_CR124","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejrad.2018.10.032","volume":"109","author":"SF Calloni","year":"2018","unstructured":"Calloni, S. F. et al. Multiparametric MR imaging of Parkinsonisms at 3 tesla: its role in the differentiation of idiopathic Parkinson\u2019s disease versus atypical Parkinsonian disorders. Eur. J. Radiol. 109, 95\u2013100 (2018).","journal-title":"Eur. J. Radiol."},{"key":"1034_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat. Commun. 14, 6750 (2023).","journal-title":"Nat. Commun."},{"key":"1034_CR126","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.neuron.2024.05.006","volume":"112","author":"H Endo","year":"2024","unstructured":"Endo, H. et al. Imaging \u03b1-synuclein pathologies in animal models and patients with Parkinson\u2019s and related diseases. Neuron 112, 2540\u20132557.e8 (2024).","journal-title":"Neuron"},{"key":"1034_CR127","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26968","volume":"32","author":"S Lehericy","year":"2017","unstructured":"Lehericy, S. et al. The role of high\u2010field magnetic resonance imaging in parkinsonian disorders: pushing the boundaries forward. Mov. Disord. 32, 510\u2013525 (2017).","journal-title":"Mov. Disord."},{"key":"1034_CR128","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/mds.27671","volume":"34","author":"AJ Espay","year":"2019","unstructured":"Espay, A. J. et al. A roadmap for implementation of patient\u2010centered digital outcome measures in Parkinson\u2019s disease obtained using mobile health technologies. Mov. Disord. 34, 657\u2013663 (2019).","journal-title":"Mov. Disord."},{"key":"1034_CR129","doi-asserted-by":"publisher","first-page":"575975","DOI":"10.3389\/fneur.2020.575975","volume":"11","author":"R Luis-Mart\u00ednez","year":"2020","unstructured":"Luis-Mart\u00ednez, R., Monje, M. H. G., Antonini, A., S\u00e1nchez-Ferro, \u00c1. & Mestre, T. A. Technology-enabled care: integrating multidisciplinary care in Parkinson\u2019s disease through digital technology. Front. Neurol. 11, 575975 (2020).","journal-title":"Front. Neurol."},{"key":"1034_CR130","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.21873\/anticanres.15663","volume":"42","author":"Y Samhouri","year":"2022","unstructured":"Samhouri, Y. et al. The trend of combined modality treatment and its outcomes in elderly patients with primary CNS lymphoma: a 12-year population-based analysis using propensity score. Anticancer. Res. 42, 1867\u20131877 (2022).","journal-title":"Anticancer. Res."},{"key":"1034_CR131","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"1034_CR132","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","volume":"326","author":"A Herskovic","year":"1992","unstructured":"Herskovic, A. et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 326, 1593\u20131598 (1992).","journal-title":"N. Engl. J. Med."},{"key":"1034_CR133","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner, W. G. et al. Trial of lixisenatide in early Parkinson\u2019s disease. N. Engl. J. Med. 390, 1176\u20131185 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1034_CR134","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664\u20131675 (2017).","journal-title":"Lancet"},{"key":"1034_CR135","doi-asserted-by":"publisher","first-page":"106080","DOI":"10.1016\/j.parkreldis.2024.106080","volume":"122","author":"KP del Giudice","year":"2024","unstructured":"del Giudice, K. P. et al. Anti-alpha synuclein and anti-tau immunotherapies: can a cocktail approach work? Parkinsonism Relat. Disord. 122, 106080 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1034_CR136","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/13543784.2020.1771693","volume":"29","author":"A Antonini","year":"2020","unstructured":"Antonini, A., Bravi, D., Sandre, M. & Bubacco, L. Immunization therapies for Parkinson\u2019s disease: state of the art and considerations for future clinical trials. Expert Opin. Investig. Drugs 29, 685\u2013695 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1034_CR137","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1212\/WNL.0000000000013218","volume":"98","author":"K Tsukita","year":"2022","unstructured":"Tsukita, K., Sakamaki-Tsukita, H. & Takahashi, R. Long-term effect of regular physical activity and exercise habits in patients with early Parkinson disease. Neurology 98, e859\u2013e871 (2022).","journal-title":"Neurology"},{"key":"1034_CR138","doi-asserted-by":"publisher","first-page":"102089","DOI":"10.1016\/j.arr.2023.102089","volume":"92","author":"R Rotondo","year":"2023","unstructured":"Rotondo, R. et al. Physical activity and neurotrophic factors as potential drivers of neuroplasticity in Parkinson\u2019s Disease: A systematic review and meta-analysis. Ageing Res. Rev. 92, 102089 (2023).","journal-title":"Ageing Res. Rev."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01034-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01034-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01034-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T09:05:33Z","timestamp":1732698333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01034-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":138,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1034"],"URL":"https:\/\/doi.org\/10.1038\/s41582-024-01034-x","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"8 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.S. has received compensation for consultancy and speaker-related activities from UCB, Britannia, AbbVie, Zambon, Bial, Ever Pharma, Synegile, Biogen, Roche, Blue Rock, Chiesi Pharmaceuticals, Lundbeck, Sunovion and Kiowa. D.B. is a business partner of SixDegrees HealthCare and has received fees from Clexio, Herantis, Theravance, Novartis and PPD. A.A. has received compensation for consultancy and speaker-related activities from UCB, Britannia, AbbVie, Zambon, Bial, Ever Pharma, Ferrer, Theravance Biopharma, Bayer, TreeFrog Therapeutics, Oligy and Medscape. He receives research support from Lundbeck, Bial, Movement Disorders Society, Horizon2020 Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081 and Fondazione Grigioni per la Malattia di Parkinson. A.E. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}